Questo sito utilizza cookies tecnici (necessari) e analitici.
Proseguendo nella navigazione accetti l'utilizzo dei cookie.

Italy-Japan approaches for tackling the Covid-19 pandemic: an update on novel vaccines and therapies

The resurgence of the SARS-Cov-2 infections makes even more urgent the quest for vaccines and therapies. After less than one year from the outbreak of the Covid-19 pandemic, almost 700 vaccines are under study worldwide and about 30 are at least in Phase III of clinical trials, a very advanced stage in such a short time. The aim of this event is to give an update on the situation in Italy and Japan in the field of Covid-19 vaccines and therapies, thus verifying the possibility of collaborations and synergies between the two countries.

VENUE: Online on Zoom
REGISTRATION: please click here
DATE AND TIME: 9 December 2020, 17.00-19.00 JST (9.00-11.00 CET)

17.00-17.08 Welcome and Opening Remarks – H.E. Giorgio Starace (Ambassador of Italy to Japan)
17.08-17.10 Introduction by the Moderator – Prof. Enrico Traversa (Scientific Counsellor, Embassy of Italy)
17.10-17.30 Japan Keynote on Vaccines – Prof. Ryuichi Morishita, Graduate School of Medicine, Osaka University, collaborating with AnGes on clinical trials
17.30-17.50 Italy Keynote on Vaccines – Dr. Alessandra Vitelli, ReiThera, Italian company developing a vaccine in Phase I (currently tested at Ospedale Spallanzani)
17.50-18.10 Japan Keynote on Therapies – Dr. Koichi Watashi, Senior Researcher, Department of Virology II, National Institute of Infectious Diseases
18.10-18.30 Italy Keynote on Therapies – Dr. Rino Rappuoli, GSK Vaccines, developing therapy based on monoclonal antibodies
18.30-19.00 Panel Discussion and Closing Remarks